Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/06/25
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical FocusGlobeNewsWire • 06/25/25
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/25
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025GlobeNewsWire • 05/07/25
Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 04/24/25
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 03/31/25
Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec ShuffleMarket Watch • 03/27/25
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/27/25
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against ModernaGlobeNewsWire • 03/03/25
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEOGlobeNewsWire • 02/25/25
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of InterferonGlobeNewsWire • 11/15/24